Atlas Trials

Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.

Clinical trial NCT01439152 · COMPLETED

Trial details

NCT number
NCT01439152
Sponsor
Bayer
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Oncology
Start date
2011-09-07
Primary completion
2016-12-31
Enrollment
148

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.